All In Biotech

NDA 020263 · Abbvie Endocrine INC

Lupron Depot-Ped Kit

Leuprolide Acetate · Intramuscular

Orphan

Last checked: Nov 19, 2026Latest source record: Nov 14, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1993

Apr 16, 1993

Approved uses

5

Original approval plus efficacy supplements

Registered trials

457

123 Phase 3, 53 recruiting

FAERS reports

8,371

6,422 serious, 1,154 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Nov 14, 2025.

LUPRON DEPOT-PED is indicated for the treatment of pediatric patients with central precocious puberty (CPP). LUPRON DEPOT-PED is a gonadotropin releasing hormone (GnRH) agonist indicated for the treatment of pediatric patients with central precocious puberty. ( 1 )

Mechanism: Leuprolide acetate, a GnRH agonist, acts as a potent inhibitor of gonadotropin secretion (LH and follicle stimulating hormone (FSH)) when given continuously in therapeutic doses.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

8 products under this application
  • LUPRON DEPOT-PED KIT · LEUPROLIDE ACETATE 45MG · POWDER, INTRAMUSCULAR · Prescription
  • LUPRON DEPOT-PED KIT · LEUPROLIDE ACETATE 11.25MG · POWDER, INTRAMUSCULAR · Prescription
  • LUPRON DEPOT-PED KIT · LEUPROLIDE ACETATE 11.25MG · POWDER, INTRAMUSCULAR · Prescription
  • LUPRON DEPOT-PED KIT · LEUPROLIDE ACETATE 3.75MG,7.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · POWDER, INTRAMUSCULAR · Discontinued
  • LUPRON DEPOT-PED KIT · LEUPROLIDE ACETATE 30MG · POWDER, INTRAMUSCULAR · Prescription
  • LUPRON DEPOT-PED KIT · LEUPROLIDE ACETATE 15MG · POWDER, INTRAMUSCULAR · Prescription
  • LUPRON DEPOT-PED KIT · LEUPROLIDE ACETATE 7.5MG,7.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · POWDER, INTRAMUSCULAR · Discontinued
  • LUPRON DEPOT-PED KIT · LEUPROLIDE ACETATE 7.5MG · POWDER, INTRAMUSCULAR · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Leuprolide" as an intervention, any sponsor and status, largest first.

All 457 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • fatigue456
  • drug ineffective446
  • off label use406
  • hot flush344
  • asthenia299
  • death286
  • fall286
  • nausea270
  • pneumonia261
  • headache252
  • injection site pain251
  • prostate cancer238

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200486
200596
200687
2007120
2008353
2009174
2010298
2011290
2012389
2013139
2014158
2015310
2016328
2017238
2018226
2019268
2020273
2021460
2022876
2023816
2024772
2025859
2026755

Recalls

1 FDA enforcement reports for this application.

  • Mar 10, 2014 · Class II · Terminated

    Defective Delivery System: Some Lupron Depot Kits may contain a syringe with a potentially defective LuproLoc needle stick protection device.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 567 on PubMed

Sponsor: AbbVie

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.